Cannabis in der Onkologie – viel Rauch um nichts?

Zusammenfassung

Die medizinische Verwendung von Cannabis hat in den letzten Jahren in Europa und Nordamerika an Popularität gewonnen. Cannabinoide sind sowohl als Fertigarzneimittel als auch in Blüten- und Extraktform verfügbar. Der vorliegende Artikel legt den Fokus auf die supportive Therapie onkologischer Patienten. Mögliche Indikationen sind Schmerzen, Chemotherapie-bedingte Übelkeit und Erbrechen, Appetitlosigkeit und Geschmacksveränderungen. Trotz des enormen Hypes um Cannabis als Medizin ist die Evidenz für dessen Anwendung bei onkologischen Patienten unzureichend. Palliativpatienten mit refraktären Symptomen könnten jedoch geeignete Kandidaten für einen Therapieversuch darstellen. Der entscheidende Parameter für die Auswahl eines Cannabis-Arzneimittels ist die THC/CBD-Ratio. Orale Einnahmeformen bieten sich gerade für Cannabis-naive und ältere Patienten an. Psychische und kardiovaskuläre Nebenwirkungen sind nicht zu unterschätzen.

Abstract

The medical use of Cannabis has gained popularity in Europe and Northern America in recent years. Cannabinoids are available as finished pharmaceuticals, flowers and extracts. This article focuses on supportive medicine for oncological patients. Possible indications are pain, chemotherapy-induced nausea and vomiting, loss of appetite and altered taste perception. Despite the enormous cannabis hype in medicine, the evidence for its use in oncology patients is insufficient. However, palliative patients with refractory symptoms could be candidates for a therapeutic trial. The key parameter for choosing a cannabis medicinal product is the THC/CBD ratio. Oral forms of administration are particularly suitable for cannabis-naive and older patients. Mental and cardiovascular side effects should not be underestimated.

Schlüsselwörter

Cannabis - Onkologie - Palliativmedizin - Supportive Therapie - THC - CBD - Cannabinoide - Endocannabinoid-System

Key words

cannabis-based medicine - medical cannabis - endocannabinoid system - oncology - palliative medicine - supportive care - THC - CBD

Publikationsverlauf

Artikel online veröffentlicht:
22. Juli 2022

• Literatur

• 1 GKV-Spitzenverband. GKV-Arzneimittel-Schnellinformation für Deutschland nach § 84 Abs. 5 SGB V.
• 2 Treister-Goltzman Y, Freud T, Press Y. et al. Trends in Publications on Medical Cannabis from the Year 2000. Popul Health Manag 2019; 22: 362-368 DOI: 10.1089/pop.2018.0113.
• 3 Schmidt-Wolf G, Cremer-Schaeffer P. 3 Jahre Cannabis als Medizin – Zwischenergebnisse der Cannabisbegleiterhebung. Bundesgesundheitsbl 2021; DOI: 10.1007/s00103-021-03285-1.
• 4 Schneider M, Hoch E, Simon R. et al. Cannabis, Cannabinoide und das Endocannabinoidsystem. In: Cannabis: Potenzial und Risiko. Berlin, Heidelberg: Springer Berlin Heidelberg; 2019: 1-36
• 5 Koch-Institut R. Krebs in Deutschland für 2017/2018. 2017: 24-31
• 6 Di Marzo V. New approaches and challenges to targeting the endocannabinoid system. Nat Rev Drug Discov 2018; 17: 623-639 DOI: 10.1038/nrd.2018.115.
• 7 Devane WA, Dysarz IiiFA, Johnson MR. et al. Determination and Characterization of a Cannabinoid Receptor in Rat Brain.
• 8 Matsuda LA, Lolait SJ, Brownstein MJ. et al. Structure of a cannabinoid receptor and functional expression of the cloned eDNA. 1990
• 9 ElSohly MA, Radwan MM, Gul W. et al. Phytochemistry of Cannabis sativa L. 2017: 1-36
• 10 Hazekamp A, Fischedick JT. Cannabis – from cultivar to chemovar. Drug Test Anal 2012; 4: 660-667 DOI: 10.1002/dta.407.
• 11 Hazekamp A, Tejkalová K, Papadimitriou S. Cannabis: From Cultivar to Chemovar II – A Metabolomics Approach to Cannabis Classification. Cannabis Cannabinoid Res 2016; 1: 202-215 DOI: 10.1089/can.2016.0017.
• 12 Russo EB. Taming THC: potential cannabis synergy and phytocannabinoid-terpenoid entourage effects LINKED ARTICLES. Br J Pharmacol 2011; 163: 1344-1364 DOI: 10.1111/bph.2011.163.issue-7.
• 13 Worth T. Unpicking the entourage effect. Nature 2019; 572: S12-S13
• 14 Bundestag, Bundesgesetzblatt, Bundestag. Gesetz zur Änderung betäubungsmittelrechtlicher und anderer Vorschriften. 2017: 403-405
• 15 Häuser W, Finn DP, Kalso E. et al. European Pain Federation (EFIC) position paper on appropriate use of cannabis-based medicines and medical cannabis for chronic pain management. Eur J Pain 2018; 22: 1547-1564 DOI: 10.1002/ejp.1297.
• 16 Häuser W, Welsch P, Klose P. et al. Efficacy, tolerability and safety of cannabis-based medicines for cancer pain A systematic review with meta-analysis of randomised controlled trials Electronic supplementary material. 2019 DOI: 10.1007/s00482-019-0373-3
• 17 Johnson JR, Burnell-Nugent M, Lossignol D. et al. Multicenter, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Study of the Efficacy, Safety, and Tolerability of THC:CBD Extract and THC Extract in Patients with Intractable Cancer-Related Pain. J Pain Symptom Manage 2010; 39: 167-179 DOI: 10.1016/J.JPAINSYMMAN.2009.06.008.
• 18 Fallon M, Giusti R, Aielli F. et al. Management of cancer pain in adult patients: ESMO Clinical Practice Guidelines. Ann Oncol 2018; 29: iv166-iv191 DOI: 10.1093/annonc/mdy152.
• 19 Smith LA, Azariah F, Lavender VT. et al. Cannabinoids for nausea and vomiting in adults with cancer receiving chemotherapy. Cochrane Database Syst Rev 2015; 2021 DOI: 10.1002/14651858.CD009464.pub2.
• 20 Duran M, Pérez E, Abanades S. et al. Preliminary efficacy and safety of an oromucosal standardized cannabis extract in chemotherapy-induced nausea and vomiting. Br J Clin Pharmacol 2010; 70: 656-663 DOI: 10.1111/j.1365-2125.2010.03743.x.
• 21 Grimison P, Mersiades A, Kirby A. et al. Oral THC:CBD cannabis extract for refractory chemotherapy-induced nausea and vomiting: a randomised, placebo-controlled, phase II crossover trial. Ann Oncol 2020; 31: 1553-1560 DOI: 10.1016/j.annonc.2020.07.020.
• 22 Leitlinienprogramm Onkologie der Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften e.V. (AWMF) DK e. V (DKG) und DK (DKH). S3-Leitlinie Supportive Therapie bei onkologischen PatientInnen. 2020
• 23 Leitlinienprogramm Onkologie Deutsche Krebsgesellschaft Deutsche Krebshilfe AWMF. Erweiterte S3-Leitlinie Palliativmedizin für Patienten mit einer nicht-heilbaren Krebserkrankung. 2021: 1-550
• 24 Hariyanto TI, Kurniawan A. Appetite problem in cancer patients: Pathophysiology, diagnosis, and treatment. Cancer Treat Res Commun 2021; 27: 100336 DOI: 10.1016/J.CTARC.2021.100336.
• 25 Strasser F, Luftner D, Possinger K. et al. Comparison of orally administered cannabis extract and delta-9- tetrahydrocannabinol in treating patients with cancer-related anorexia-cachexia syndrome: A multicenter, phase III, randomized, double-blind, placebo-controlled clinical trial from the Cannab. J Clin Oncol 2006; 24: 3394-3400 DOI: 10.1200/JCO.2005.05.1847.
• 26 Turcott JG, del Rocío Guillen Núñez M, Flores-Estrada D. et al. The effect of nabilone on appetite, nutritional status, and quality of life in lung cancer patients: a randomized, double-blind clinical trial. Support Care Cancer 2018; 26: 3029-3038 DOI: 10.1007/s00520-018-4154-9.
• 27 Brisbois TD, De Kock IH, Watanabe SM. et al. Delta-9-tetrahydrocannabinol may palliate altered chemosensory perception in cancer patients: results of a randomized, double-blind, placebo-controlled pilot trial. Ann Oncol 2011; 22: 2086-2093 DOI: 10.1093/annonc/mdq727.
• 28 Mücke M, Weier M, Carter C. et al. Systematic review and meta-analysis of cannabinoids in palliative medicine. R E V I E W 2018; DOI: 10.1002/jcsm.12273.
• 29 Arends J, Strasser F, Gonella S. et al. Cancer cachexia in adult patients: ESMO Clinical Practice Guidelines. ESMO Open 2021; 6: 100092 DOI: 10.1016/j.esmoop.2021.100092.
• 30 Arends AJ, Bertz H, Bischoff SC. et al. Klinische Ernährung in der Onkologie S3-Guideline of the German Society for Nutritional Medicine (DGEM) in Cooperation with the DGHO, the ASORS and the AKE Clinical Nutrition in Oncology. Klin Ernährung … Aktuel Ernahrungsmed 2015; 40: 1-74 DOI: 10.1055/s-0035-1552741.
• 31 Whiting PF, Wolff RF, Deshpande S. et al. Cannabinoids for medical use: A systematic review and meta-analysis. JAMA – J Am Med Assoc 2015; 313: 2456-2473 DOI: 10.1001/jama.2015.6358.
• 32 Schloss J, Lacey J, Sinclair J. et al. A Phase 2 Randomised Clinical Trial Assessing the Tolerability of Two Different Ratios of Medicinal Cannabis in Patients With High Grade Gliomas. Front Oncol 2021; 11: 1687 DOI: 10.3389/fonc.2021.649555.
• 33 Aminilari M, Wang L, Neumark S. et al. Medical cannabis and cannabinoids for impaired sleep: a systematic review and meta-analysis of randomized clinical trials. SLEEPJ 2021; 2021: 1-11 DOI: 10.1093/sleep/zsab234.
• 34 Bar-Lev Schleider L, Mechoulam R, Lederman V. et al. Prospective analysis of safety and efficacy of medical cannabis in large unselected population of patients with cancer. Eur J Intern Med 2018; 49: 37-43 DOI: 10.1016/j.ejim.2018.01.023.
• 35 Friemel CM, Keller RVon, Kabisch BAJ. Kurzbericht CaPRiS. 2017
• 36 Blessing EM, Steenkamp MM, Manzanares J. et al. Cannabidiol as a Potenzial Treatment for Anxiety Disorders. Neurotherapeutics 2015; 12: 825-836 DOI: 10.1007/s13311-015-0387-1.
• 37 Martin EL, Strickland JC, Schlienz NJ. et al. Antidepressant and Anxiolytic Effects of Medicinal Cannabis Use in an Observational Trial. Front Psychiatry 2021; 12: 1554 DOI: 10.3389/fpsyt.2021.729800.
• 38 Chesney E, Oliver D, Green A. et al. Adverse effects of cannabidiol: a systematic review and meta-analysis of randomized clinical trials. Neuropsychopharmacology 2020; 45: 1799-1806 DOI: 10.1038/s41386-020-0667-2.
• 39 Grotenhermen F. Pharmacokinetics and Pharmacodynamics of Cannabinoids. Clin Pharmacokinet 2003; 42: 327-360 DOI: 10.2165/00003088-200342040-00003.
• 40 Russo E, Guy GW. A tale of two cannabinoids: The therapeutic rationale for combining tetrahydrocannabinol and cannabidiol. Med Hypotheses 2006; 66: 234-246 DOI: 10.1016/J.MEHY.2005.08.026.
• 41 U.S. Food and Drug Administration. Epidiolex. Full Prescr Inf; 2018
• 42 Watkins PB, Church RJ, Li J. et al. Cannabidiol and Abnormal Liver Chemistries in Healthy Adults: Results of a Phase I Clinical Trial. Clin Pharmacol Ther 2021; 109: 1224-1231 DOI: 10.1002/cpt.2071.
• 43 Müller-Vahl K, Grotenhermen F. Medizinisches Cannabis – Die wichtigsten Änderungen. Dtsch Ärztebl 2017; 114: 1-3
• 44 Alsherbiny MA, Li CG. Medicinal Cannabis-Potenzial Drug Interactions. Med (Basel, Switzerland) 2018: 6 DOI: 10.3390/medicines6010003
• 45 Geffrey AL, Pollack SF, Bruno PL. et al. Drug-drug interaction between clobazam and cannabidiol in children with refractory epilepsy. Epilepsia 2015; 56: 1246-1251 DOI: 10.1111/epi.13060.
• 46 Wörmann B. Onkologie DDG für H und M. Medizinischer Cannabis und Cannabinoide. Onkopedia; 2021
• 47 Taha T, Meiri D, Talhamy S. et al. Cannabis Impacts Tumor Response Rate to Nivolumab in Patients with Advanced Malignancies. Oncologist 2019; 24: 549-554 DOI: 10.1634/theoncologist.2018-0383.
• 48 Hinz B, Ramer R. Anti-tumour actions of cannabinoids. Br J Pharmacol 2019; 176: 1384-1394 DOI: 10.1111/bph.14426.
• 49 Hanif F, Muzaffar K, Perveen K. et al. Glioblastoma Multiforme: A Review of its Epidemiology and Pathogenesis through Clinical Presentation and Treatment. Asian Pac J Cancer Prev 2017; 18: 3-9 DOI: 10.22034/APJCP.2017.18.1.3.
• 50 Twelves C, Sabel M, Checketts D. et al. A phase 1b randomised, placebo-controlled trial of nabiximols cannabinoid oromucosal spray with temozolomide in patients with recurrent glioblastoma. Br J Cancer 2021; 124: 1379-1387 DOI: 10.1038/s41416-021-01259-3.
• 51 Mc Donagh MS, Morasco BJ, Wagner J. et al. Cannabis-Based Products for Chronic Pain. A Systematic Review. Ann Intern med 2022; DOI: 10.7326/M21-4520.